Drug Profile

Valiloxibic acid - XWPharma

Alternative Names: XWL-008

Latest Information Update: 28 Jul 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator XW labs
Developer XWPharma
Class Amines; Butyric acids; Esters; Sleep disorder therapies; Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Narcolepsy
New Molecular Entity Yes

28 Jul 2022 No recent reports of development identified for phase-I development in Narcolepsy in China
17 Sep 2020 XW Laboratories is now called XWPharma
24 Jun 2019 Phase-I clinical trials in Narcolepsy in China (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com